GP2 peptide
DRACPC ID DRACPC0055
Active Ingredients GP2 peptide
Description A HER2/Neu-derived epitope (amino acids 654-662). GP2 combined with granulocyte-macrophage colony-stimulating factor (GM-CSF) as a vaccine, with potential antineoplastic and immunoadjuvant activity. Upon vaccination, GP2 may activate the immune system to mount a cytotoxic T-lymphocyte (CTL) immune response against HER2/Neu expressing cancer cells. GM-CSF may potentiate a tumor-specific cytotoxic T-lymphocyte (CTL) response against cancer cells expressing the HER2/Neu antigen. HER2/neu, a tumor associated antigen (TAA), is overexpressed in a variety of tumor cell types and is highly immunogenic.
Synonyms GP2; HER2/neu (654-662) GP2; GP2 peptide
Type Biotech
Disease Breast cancer
Classification
Peptide and derivative Vaccine
Structure Information
Molecular Formula C42H77N9O11
Molecular Weight 884.1
Active Sequence IISAVVGIL
Sequence Length 9
Modification None
IUPAC Name (2S)-2-[[(2S,3S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S,3S)-2-amino-3-methylpentanoyl]amino]-3-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]acetyl]amino]-3-methylpentanoyl]amino]-4-methylpentanoic acid
InChI InChI=1S/C42H77N9O11/c1-14-23(10)30(43)37(56)51-34(25(12)16-3)41(60)47-28(19-52)36(55)45-26(13)35(54)49-32(22(8)9)39(58)50-31(21(6)7)38(57)44-18-29(53)48-33(24(11)15-2)40(59)46-27(42(61)62)17-20(4)5/h20-28,30-34,52H,14-19,43H2,1-13H3,(H,44,57)(H,45,55)(H,46,59)(H,47,60)(H,48,53)(H,49,54)(H,50,58)(H,51,56)(H,61,62)/t23-,24-,25-,26-,27-,28-,30-,31-,32-,33-,34-/m0/s1
InChI_Key XQIXDDUJIUUELO-JZOOTMHBSA-N
SMILES CC(C)C[C@H](NC([C@@H](NC(CNC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](N)[C@@H](C)CC)=O)[C@@H](C)CC)=O)CO)=O)C)=O)C(C)C)=O)C(C)C)=O)=O)[C@@H](C)CC)=O)C(O)=O
External Codes
PubChem CID 448183
DrugBank Accession Number DB16180
NCI Thesaurus Code C91720
UNII FQA52PV28G GSRS
CAS 160790-21-6
Drug approval
Drug indication
Investigated for use/treatment in breast cancer.
The drug is not approved.
| ClinicalTrials.gov Identifier | Title | Condition or disease | Phase | Purpose |
|---|---|---|---|---|
| NCT03014076 | Phase Ib Trial of Combination Immunotherapy With HER2/Neu Peptide GP2 + GM-CSF Vaccine and Trastuzumab in Breast Cancer Patients | Breast Cancer | Phase 1 | Treatment |
| NCT00524277 | Phase II Trial of the HER2/Neu Peptide GP2 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2+ OR the Modified HER2/Neu Peptide AE37 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2- Node-Positive and High-Risk Node-Negative Breast Cancer Patients | Breast Cancer | Phase 2 | Prevention |
| NCT05232916 | A Randomized, Multicenter, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects With Residual Disease or High-Risk PCR After Both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) | Breast Cancer | Phase 3 | Prevention |
More clinical information is obtained from ClinicalTrials.gov.
